|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of liver biopsy in hepatocellular carcinoma显示文摘The role of liver biopsy in the diagnosis of hepatocellular carcinoma(HCC)has been challenged over time by the ability of imaging techniques to characterize liver lesions in patients with known cirrhosis.In fact,in the diagnostic algorithm for this tumor,histology is currently relegated to controversial cases.Furthermore,the risk of complications,such as tumor seeding and bleeding,as well as inadequate sampling have further limited the use of liver biopsy for HCC management.However,there is growing evidence of prognostic and therapeutic information available from microscopic and molecular analysis of HCC and,as the information content of the tissue sample increases,the advantages of liver biopsy might modify the current risk/benefit ratio.We herein review the role and potentiality of liver biopsy in the diagnosis and management of HCC.As the potentiality of precision medicine comes to the management of HCC,it will be crucial to have rapid pathways to define prognosis,and even treatment,by identifying the patients who could most benefit from target-driven therapies.All of the above reasons suggest that the current role of liver biopsy in the management of HCC needs substantial reconsideration. | Luca Di Tommaso Marco Spadaccini Matteo Donadon Nicola Personeni Abubaker Elamin Alessio Aghemo Ana Lleo | 2019 | World Journal of Gastroenterology2019，25，40： | 11 |
| 2 | Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma显示文摘 | Nicola Personeni Silvia Bozzarelli Tiziana Pressiani Lorenza Rimassa Maria Chiara Tronconi Francesco Sclafani Carlo Carnaghi Vittorio Pedicini Laura Giordano Armando Santoro | 2012 | Journal of Hepatology2012，，1： | 3 |
| 3 | Targeted agents for second-line treatment of advanced hepatocellular carcinoma显示文摘Over the past ten years,sorafenib,a multikinase inhibitor,has been the standard of care for patients with unresectable hepatocellular carcinoma(HCC)and wellpreserved liver function.Recently,lenvatinib,a different multikinase inhibitor,was shown to be non-inferior to sorafenib,in terms of survival,while all other agents previously tested failed to prove non-inferiority(or superiority)when compared to sorafenib.Similarly,in the second-line setting,most investigational drugs failed to provide better survival outcomes than placebo.However,in the last 2 years three positive phase III trials have been published in this setting.The RESORCE trial,a phase III study evaluating regorafenib in HCC patients who experienced disease progression after first-line treatment with sorafenib,showed better outcomes with regorafenib compared to placebo.More recently,the phase III CELESTIAL trial demonstrated the superiority of cabozantinib,a multikinase inhibitor targeting vascular endothelial growth factor receptor,MET,and AXL,vs placebo in the second-and third-line setting in patients progressing on or intolerant to sorafenib.The survival benefits of a sustained anti-angiogenic inhibition were demonstrated also with ramucirumab in the phase III REACH-2 trial in patients previously treated with sorafenib and who had high baseline alpha-fetoprotein levels.Overall,the adverse events reported in these trials were in line with the known safety profiles of the tested agents.After nearly a decade of a certain degree of stagnation,we are now witnessing a period of novel therapeutic advances with multikinase inhibitors and monoclonal antibodies that will likely change the treatment scenario of HCC. | Nicola Personeni Tiziana Pressiani Silvia Bozzarelli Lorenza Rimassa | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 2 |
| 4 | Evolution of devices in diabetes management显示文摘 | Penfornis A Personeni E Borot S | 2011 | Diabetes Technol Ther2011，131，： | 1 |
| 5 | Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/ phosphorylated epidermal growth factor receptor in metastatic coloreetal cancer 显示文摘 | Personeni N Hendlisz A Gallez J | 2005 | Semin Oncol2005，32，9： | 1 |
| 6 | Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib:does intratu- moral heterogeneity matter显示文摘 | Personeni N | 2006 | J Clin 0neol2006，24，34： | 1 |
| 7 | HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma显示文摘 | Personeni N Nizzoli R | 2003 | Cancer2003，99，5： | 1 |
| 8 | Achievements in systemic therapies in the pregenomic era in metastatic breast cancer显示文摘 | Colozza M de Azambuja E Personeni N | 2007 | Oncologist2007，12，： | 1 |
| 9 | Usefulness of alpha-feto-protein response in patients treated with sorafenib for advanced hepa- tocellular carcinoma显示文摘 | Personeni N Bozzarelli S Pressiani T | 2012 | J Hepatology2012，57，1： | 1 |
| 10 | A structure-based design approach to the development of novel, reversible ACHE inhibitors显示文摘 | BENTLEY P D FLETCHER R J | 2001 | J MedChem2001，44，： | 1 |
| 11 | Vaginal Dinoprostone Versus Intravenous Oxytocin for Labor Induction in Patients Not Responsive to a First Dose of Dinoprostone:A Randomized Prospective Study显示文摘 | Antonazzo P Laoreti A Personeni C | 2015 | Reprod Sci2015，22，3： | 1 |
| 12 | Molecular determin-ants of outcome in sorafenib-treated patients with hepatocellular carcinoma显示文摘 | Personeni N Rimassa L Pressiani T | 2013 | J Cancer Res Clin Oncol2013，139，7： | 1 |
| 13 | Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer显示文摘 | Personeni N Hendlisz A Gallez J | 2005 | Semin Oncol2005，32，9： | 1 |
| 14 | Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer显示文摘 | Personeni N Hendlisz A Gallez J | 2005 | Semin Oncol2005，32，6： | 1 |
| 15 | Usefulness of alpha- fetoprotein response in patients treated with sorafenib for ad- vanced hepatocellular carcinoma显示文摘 | Personeni N Bozzarelli S Pressiani T | 2012 | J Hepatol2012，57，1： | 1 |
| 16 | Usefulness of alpha - fetoprotein response in patients treated with sorafenib for advanced hepatoeellular carcinoma显示文摘 | Personeni N Bozzarelli S Pressiani T | 2012 | J Hepatol2012，57，1： | 1 |
| 17 | Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated withcetuximab: a fluorescent in situ hybridization study显示文摘 | PERSONENI N FIEUWS S PIESSEVAUX H | 2008 | Clin CancerRes2008，14，18： | 1 |
| 18 | Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 显示文摘 | Personeni N Rimassa L Pressiani T | 2013 | J Cancer Res Clin Oncol2013，139，7： | 1 |
| 19 | Evolution of De-vices in Diabetes Management显示文摘 | Alfred Penfornis Estelle Personeni Sophie Borot | 2011 | Diabetes Technology&Therapeu-tics2011，13，1： | 1 |
| 20 | Molecular determinants of outcome in sorafenib- treated patients with hepatocellular carcinoma显示文摘 | PERSONENI N RIMASSA L PRESSIANI T | 2013 | J Cancer Res Clin Oncol2013，139，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员